# HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional) (RFA-NS-27-007)

**Plain-English Eligibility Score:** 80/100

| Field | Value |
|---|---|
| Opportunity number | RFA-NS-27-007 |
| Title | HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional) |
| Agency | National Institutes of Health |
| Status | posted |
| Posted / open date | 2026-06-16 |
| Close date | 2029-02-20 |
| Award ceiling | n/a |
| Award floor | n/a |
| Estimated total funding | $11,000,000 |
| Funding category | Health |
| Eligible applicants | State governments; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Public and State controlled institutions of higher education; Private institutions of higher education; Native American tribal organizations (other than Federally recognized tribal governments); Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Special district governments; Public housing authorities/Indian housing authorities; City or township governments; Others (see text field entitled "Additional Information on Eligibility" for clarification); County governments; Independent school districts; For profit organizations other than small businesses; Small businesses; Native American tribal governments (Federally recognized) |
| Eligibility notes | Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Foreign Organizations/International CollaborationsNon-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are not allowed. |
| CFDA / Assistance listing | 93.395, 93.866, 93.839, 93.867, 93.838, 93.846, 93.840, 93.213, 93.273, 93.853, 93.837, 93.233, 93.279, 93.865 |
| Summary | The purpose of this Notice of Funding Opportunity (NOFO) is to support the preclinical optimization and development of safe, effective, and non-addictive small molecule and biologic therapeutics for the treatment of pain. The goal of the program is to accelerate the advancement of promising early-stage therapeutic candidates and facilitate their readiness for Phase II clinical trials. Applicants must have a promising small molecule or biologic lead candidate for optimization, a strong biological rationale for the proposed approach, and established assays to guide the optimization process. The scope of the program includes lead optimization, early-stage development activities, IND-enabling st |
| Agency contact | PTDP@ninds.nih.gov |

## Why this score
- Small businesses are listed as eligible applicants.
- Nonprofits are listed as eligible applicants.
- 838 days until the deadline: enough time to prepare a strong application.

Source: Grants.gov (U.S. Department of Health and Human Services) (https://www.grants.gov/search-results-detail/359161). Last refreshed: 2026-11-04T18:11:59.874Z.
Data from Grants.gov. Always read the full notice of funding opportunity before applying. Informational only; not legal or grant-writing advice.